Mizuho Maintains BrightSpring Health Services (BTSGU) Outperform Recommendation

Mizuho maintained an Outperform rating on BrightSpring Health Services (BTSGU) on October 17, 2025, with an average one-year price target of $102.42, suggesting a 1.11% upside from its $101.29 closing price. This analyst outlook coincides with growing institutional interest, as the number of funds holding BTSGU increased by 4.84% and total institutional shares rose 3.59% to 10.17 million in the last quarter, with the average portfolio weight dedicated to the stock also increasing by 18.37%.

Analysis

Mizuho recently reiterated an "Outperform" recommendation for BrightSpring Health Services (BTSGU) on October 17, 2025. The average one-year price target stands at $102.42, suggesting a modest 1.11% upside from its latest closing price of $101.29. This target is supported by a range from $86.19 to $146.94, indicating varied analyst perspectives.

Institutional interest in BTSGU has shown a notable increase, with 65 funds now reporting positions, a 4.84% rise quarter-over-quarter. Total institutional ownership grew by 3.59% to 10.166 million shares, and the average portfolio weight dedicated to the stock increased by 18.37%. This suggests a broader positive sentiment among institutional investors.

Key institutional movements include Aequim Alternative Investments increasing its stake by 11.63% to 1.29 million shares and Bank Of Montreal initiating a substantial new position of 1.208 million shares. Wolverine Asset Management also significantly raised its holdings by 48.04%. However, iShares Preferred and Income Securities ETF (PFF) and Voya Investment Management (VOYA) reduced their share counts by 8.99% and 7.35% respectively, presenting a mixed picture of individual fund conviction despite the overall institutional accumulation.

Key Decisions for Investors

• Investors should consider the moderately positive sentiment and increasing aggregate institutional ownership as potential supportive factors for BTSGU's valuation.
• Monitor the company's performance against the projected annual non-GAAP EPS of $0.59 to validate the analyst's 'Outperform' rating and price target.
• Evaluate the mixed individual fund actions, noting significant new positions alongside some reductions, to understand the nuances of institutional conviction beyond headline figures.